Molecular targets of metformin antitumor action
- PMID: 27362768
- DOI: 10.1016/j.pharep.2016.04.021
Molecular targets of metformin antitumor action
Abstract
Epidemiological studies have shown that metformin, a first line therapeutic agent for diabetes mellitus, reduced the risk of developing various malignancies. Several preclinical studies established some possible mechanisms of its anticancer effects. The primary effect of metformin action is a decrease in cell energy status, which activates AMP-activated kinase (AMPK), a cellular metabolic sensor. This event is followed by a decrease in serum concentrations of insulin and insulin growth factor I (IGF-I), the potent mitogens for cancer cells. In addition to the indirect mode of action, metformin may exhibit direct inhibitory effect on cancer cells by targeting mammalian target of rapamycin (mTOR) signaling and anabolic processes. This review gathers information on mechanisms of metformin antitumor activity, with special attention given to the impact of this antidiabetic drug on insulin/PI3K/mTOR and AMPK signaling. Furthermore, the factors required for this novel activity of metformin are discussed.
Keywords: Antitumor properties; Metformin; Molecular mechanisms.
Copyright © 2016 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
Similar articles
-
Metformin in cancer therapy: a new perspective for an old antidiabetic drug?Mol Cancer Ther. 2010 May;9(5):1092-9. doi: 10.1158/1535-7163.MCT-09-1186. Epub 2010 May 4. Mol Cancer Ther. 2010. PMID: 20442309 Review.
-
[New perspectives for metformin in cancer therapy].Ann Endocrinol (Paris). 2013 May;74(2):130-6. doi: 10.1016/j.ando.2013.02.002. Epub 2013 Apr 12. Ann Endocrinol (Paris). 2013. PMID: 23587351 Review. French.
-
Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer.Clin Cancer Res. 2010 May 1;16(9):2505-11. doi: 10.1158/1078-0432.CCR-09-2229. Epub 2010 Apr 13. Clin Cancer Res. 2010. PMID: 20388847 Free PMC article.
-
Inhibition of midkine by metformin can contribute to its anticancer effects in malignancies: A proposal mechanism of action of metformin in context of endometrial cancer prevention and therapy.Med Hypotheses. 2020 Jan;134:109420. doi: 10.1016/j.mehy.2019.109420. Epub 2019 Oct 3. Med Hypotheses. 2020. PMID: 31634770
-
Metformin as an Anticancer Agent.Trends Pharmacol Sci. 2018 Oct;39(10):867-878. doi: 10.1016/j.tips.2018.07.006. Epub 2018 Aug 24. Trends Pharmacol Sci. 2018. PMID: 30150001 Free PMC article. Review.
Cited by
-
Metformin, the Rise of a New Medical Therapy for Endometriosis? A Systematic Review of the Literature.Front Med (Lausanne). 2021 May 11;8:581311. doi: 10.3389/fmed.2021.581311. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34046415 Free PMC article.
-
Phosphorylation of PDHA by AMPK Drives TCA Cycle to Promote Cancer Metastasis.Mol Cell. 2020 Oct 15;80(2):263-278.e7. doi: 10.1016/j.molcel.2020.09.018. Epub 2020 Oct 5. Mol Cell. 2020. PMID: 33022274 Free PMC article.
-
Targeting Altered Energy Metabolism in Colorectal Cancer: Oncogenic Reprogramming, the Central Role of the TCA Cycle and Therapeutic Opportunities.Cancers (Basel). 2020 Jun 29;12(7):1731. doi: 10.3390/cancers12071731. Cancers (Basel). 2020. PMID: 32610612 Free PMC article. Review.
-
[6]-Gingerol Suppresses Oral Cancer Cell Growth by Inducing the Activation of AMPK and Suppressing the AKT/mTOR Signaling Pathway.In Vivo. 2021 Nov-Dec;35(6):3193-3201. doi: 10.21873/invivo.12614. In Vivo. 2021. PMID: 34697150 Free PMC article.
-
Metformin in Lung Cancer: Review of in Vitro and in Vivo Animal Studies.Cancers (Basel). 2017 May 6;9(5):45. doi: 10.3390/cancers9050045. Cancers (Basel). 2017. PMID: 28481268 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous